DRREDDY Stock Overview
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for DRREDDY from our risk checks.
Dr. Reddy's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,218.75 |
| 52 Week High | ₹6,505.90 |
| 52 Week Low | ₹4,384.05 |
| Beta | 0.34 |
| 1 Month Change | 1.37% |
| 3 Month Change | 6.20% |
| 1 Year Change | 26.43% |
| 3 Year Change | 21.88% |
| 5 Year Change | 112.98% |
| Change since IPO | 1,295.51% |
Recent News & Updates
Recent updates
There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18
Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?
Sep 28Do Dr. Reddy's Laboratories' (NSE:DRREDDY) Earnings Warrant Your Attention?
Aug 17Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Shares Could Be 33% Above Their Intrinsic Value Estimate
Jul 21Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹30.00
Jul 08Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Larger Dividend Than Last Year At ₹30.00
Jun 22Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹30.00
Jun 07Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
May 24Shareholder Returns
| DRREDDY | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.4% | -0.1% | 1.8% |
| 1Y | 26.4% | 55.9% | 46.4% |
Return vs Industry: DRREDDY underperformed the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: DRREDDY underperformed the Indian Market which returned 46.4% over the past year.
Price Volatility
| DRREDDY volatility | |
|---|---|
| DRREDDY Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: DRREDDY has not had significant price volatility in the past 3 months.
Volatility Over Time: DRREDDY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 25,863 | Erez Israeli | www.drreddys.com |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.
Dr. Reddy's Laboratories Limited Fundamentals Summary
| DRREDDY fundamental statistics | |
|---|---|
| Market cap | ₹1.04t |
| Earnings (TTM) | ₹52.21b |
| Revenue (TTM) | ₹271.30b |
19.8x
P/E Ratio3.8x
P/S RatioIs DRREDDY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DRREDDY income statement (TTM) | |
|---|---|
| Revenue | ₹271.30b |
| Cost of Revenue | ₹113.18b |
| Gross Profit | ₹158.12b |
| Other Expenses | ₹105.92b |
| Earnings | ₹52.21b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 313.51 |
| Gross Margin | 58.28% |
| Net Profit Margin | 19.24% |
| Debt/Equity Ratio | 6.0% |
How did DRREDDY perform over the long term?
See historical performance and comparison